Prof Federico Roncaroli

Clinical Reader

View graph of relations

Overview

Dr Roncaroli qualified in medicine and trained as histopathologist at the University of Turin in Italy. He moved to Bologna, Italy as a consultant in an academic department of Histopathology where he developed his interest in neuropathology. After a period at Mayo Clinic, Rochester USA with Professor Bernd Scheithauer, he was appointed clinical senior lecturer in neuropathology at Imperial College, London. He moved to the University of Manchester in September 2015.

Dr Roncaroli’s field of expertise is neuropathology encompassing the examination of brain and pituitary tumours, muscle and nerve biopsies, cerebrospinal fluid cytology, and post-mortem brains.

At Imperial College, he was responsible of the neuropathology diagnostic service, established a brain tumour registry and a biobank for brain and pituitary tumours that was part of the Imperial Healthcare Tissue Bank. He was also the referring neuropathologist of the UK Multiple Sclerosis and Parkinson’s Disease Tissue Bank. He retained a honorary contract at Imperial College and remained part of the neuropathology team.

In Manchester, he has created a dedicated brain and pituitary tumour biobank, established the molecular diagnostic service for brain tumours and joined the Manchester Brain Bank chaired by Professor David Mann.

Most of Dr Roncaroli’s research focuses on brain and pituitary tumours. His group applies quantitative immunohistochemical techniques, 3D tissue reconstructions, confocal scanning laser microscopy and laser microdissection to human brain tissue from surgical samples and post-mortem brains and integrate tissue analysis with cell culture models and gene expression studies.

The group is currently working on a mitochondrial membrane molecule called the translocator protein (mTSPO) in collaboration with Mr David Coope, Professor Karl Herholz and Professor Alan Jackson at the Wolfson Molecular Imaging Centre. By combining molecular imaging data with tissue analysis and in vitro cell models, we have shown mTSPO to be an ideal PET imaging target for human gliomas and showed his value as predictive biomarker for transformation of low grade into anaplastic, aggressive tumours. Together with professor Turkheimer and his group at the Institute of Psychiatry in London, we have also recently contributed to accurate modelling of mTSPO in normal brain vessels. 

Memberships of committees and professional bodies

1995-present:              American Association for Cancer Research.

2004-present:              British Neuropathological Society

2004-present:              British Society of Endocrinology

2006-present:              British Neuro-oncology Society

2005-present:              Fellow Royal Society of Medicine

2011-present:              European Neuroendocrine Association

Areas of expertise

Research Networks and Beacons

Related information